Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DuoTrav APS versus XALACOM for ocular surface tolerance in glaucoma or ocular hypertension
NL-OMON35130Phase 3Active, not recruiting
- Sponsor
- Alcon Inc.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of travoprost + timolol and timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Mean NEI VFQ-25 composite score. Started Nov 2010; status: active, not recruiting.
02
Drugs
travoprost + timololtimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NL-OMON35130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35130.